RCEL Stock Analysis: Buy, Sell, or Hold?
RCEL - Avita Medical, Inc. Common Stock
$3.77
0.07 (1.89%)
▲
5d:
-5.51%
30d:
-21.62%
90d:
+9.28%
HOLD
LOW Confidence
Analysis Updated: Apr 1, 2026 12:00 AM ET
Earnings: May 14, 2026
Smart Money Accumulation
RCEL is down 12.7% this week, but smart money is accumulating calls. Top strike: $5 2026-04-17 with 277 OI. Call ratio: 100% View Scanner →
Strength: 10.0/10
Get Alerted When RCEL Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: RCEL shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: RCEL shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
In-depth Analysis How we analyze
Valuation Analysis: RCEL is currently trading at $3.77, which is considered oversold relative to its 30-day fair value range of $3.95 to $5.01. From a valuation perspective, the stock is trading at a discount (Forward PE: -13.0) compared to its historical average (8.0). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, RCEL is in a uptrend. Immediate support is located at $3.53, while resistance sits at $4.25.
Market Sentiment: RCEL has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $8.37 (+122.1%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, RCEL is in a uptrend. Immediate support is located at $3.53, while resistance sits at $4.25.
Market Sentiment: RCEL has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $8.37 (+122.1%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Fair Price Range
$3.95 -
$5.01
Company Quality Score
44/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
61.9%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 122.1% below Wall St target ($8.37)
- BULLISH: Market expects only 0% annual growth - appears undervalued
- CAUTION: Recommendation downgraded due to -5.5% 5-day decline
Fair Price Analysis
30-Day Fair Range
$3.95 -
$5.01
Current vs Fair Value
OVERSOLD
Support & Resistance Levels
Support Level
$3.53
Resistance Level
$4.25
Current Trend
Uptrend
Technical data as of
Apr 1, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-12.96
Wall Street Target
$8.37
(+122.1%)
Revenue Growth (YoY)
-4.3%
Profit Margin
-67.8%
PE vs Historical
-13.0 vs 8.0
CHEAP
Share & Embed Analysis
Last updated: April 02, 2026 3:57 AM ET
Data refreshes hourly during market hours. Next update: 4:57 AM
Data refreshes hourly during market hours. Next update: 4:57 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is RCEL showing a specific setup today?
Insider Activity (6 Months)
1
Buys
0
Sells
+
Net
INSIDERS BUYING
Recent Transactions
David D O'toole
BUY
3000 shares
2026-02-19
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BSX
Boston Scientific Corp |
STRONG BUY
34 analysts |
$102 | 61 BUY |
|
SYK
Stryker Corporation |
BUY
32 analysts |
$424 | 59 HOLD |
|
DXCM
DexCom Inc |
STRONG BUY
26 analysts |
$86 | 54 HOLD |
|
ABT
Abbott Laboratories |
BUY
28 analysts |
$133 | 59 HOLD |
|
MDT
Medtronic PLC |
BUY
32 analysts |
$111 | 63 BUY |
